Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
Roberto IacovelliChiara CiccareseGiuseppe FornariniFrancesco MassariDavide BimbattiClaudia MosilloSara Elena RebuzziVincenzo Di NunnoMassimiliano GrassiEmanuela FantinelAndrea ArdizzoniGiampaolo TortoraPublished in: British journal of clinical pharmacology (2019)
This prospective study revealed a modest risk of developing left ventricular systolic dysfunction related to cabozantinib. A lack of correlation between elevated cardiac biomarkers and reduced LVEF at different time-points was detected. Assessments of the cardiac function should be reserved at the occurrence of clinical symptoms.
Keyphrases
- metastatic renal cell carcinoma
- left ventricular
- heart failure
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- blood pressure
- risk assessment
- acute myocardial infarction
- prognostic factors
- hypertrophic cardiomyopathy
- oxidative stress
- cardiac resynchronization therapy
- mitral valve
- acute coronary syndrome
- aortic valve
- patient reported
- atrial fibrillation
- data analysis
- transcatheter aortic valve replacement